Daiichi Sankyo Co Ltd (DSNKY)
33.37
+0.67
(+2.05%)
USD |
OTCM |
Apr 30, 15:59
Daiichi Sankyo Enterprise Value: 55.29B for April 29, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 29, 2024 | 55.29B |
| April 26, 2024 | 54.33B |
| April 25, 2024 | 51.76B |
| April 24, 2024 | 51.07B |
| April 23, 2024 | 50.67B |
| April 22, 2024 | 50.34B |
| April 19, 2024 | 50.46B |
| April 18, 2024 | 49.31B |
| April 17, 2024 | 48.48B |
| April 16, 2024 | 49.11B |
| April 15, 2024 | 48.83B |
| April 12, 2024 | 49.80B |
| April 11, 2024 | 49.67B |
| April 10, 2024 | 49.02B |
| April 09, 2024 | 51.08B |
| April 08, 2024 | 51.84B |
| April 05, 2024 | 52.32B |
| April 04, 2024 | 52.09B |
| April 03, 2024 | 52.44B |
| April 02, 2024 | 51.05B |
| April 01, 2024 | 51.68B |
| March 31, 2024 | 53.58B |
| March 28, 2024 | 53.29B |
| March 27, 2024 | 55.09B |
| March 26, 2024 | 54.13B |
| Date | Value |
|---|---|
| March 25, 2024 | 53.62B |
| March 22, 2024 | 54.80B |
| March 21, 2024 | 55.03B |
| March 20, 2024 | 55.72B |
| March 19, 2024 | 55.11B |
| March 18, 2024 | 55.49B |
| March 15, 2024 | 54.25B |
| March 14, 2024 | 52.75B |
| March 13, 2024 | 52.18B |
| March 12, 2024 | 54.21B |
| March 11, 2024 | 54.75B |
| March 08, 2024 | 54.80B |
| March 07, 2024 | 55.32B |
| March 06, 2024 | 55.74B |
| March 05, 2024 | 54.92B |
| March 04, 2024 | 54.84B |
| March 01, 2024 | 56.34B |
| February 29, 2024 | 55.30B |
| February 28, 2024 | 56.59B |
| February 27, 2024 | 57.91B |
| February 26, 2024 | 57.70B |
| February 23, 2024 | 55.71B |
| February 22, 2024 | 55.49B |
| February 21, 2024 | 55.51B |
| February 20, 2024 | 56.34B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
26.45B
Minimum
Aug 06 2021
66.59B
Maximum
Nov 27 2020
45.47B
Average
46.30B
Median
Nov 16 2023
Enterprise Value Benchmarks
| AstraZeneca PLC | 259.37B |
| Eisai Co Ltd | -- |
| Takeda Pharmaceutical Co Ltd | 72.15B |
| Nxera Pharma Co Ltd | 972.08M |
| PeptiDream Inc | 1.250B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 250.42M |
| Revenue (Quarterly) | 2.887B |
| Total Expenses (Quarterly) | 2.772B |
| EPS Diluted (Quarterly) | 0.1305 |
| Gross Profit Margin (Quarterly) | 75.59% |
| Profit Margin (Quarterly) | 8.68% |
| Earnings Yield | 2.18% |
| Operating Earnings Yield | 2.28% |
| Normalized Earnings Yield | 2.177 |